Anti-IL11RA Antibody (X209)  (Synonyms: EnX209)

Anti-IL11RA Antibody (X209) (EnX209) is a human-derived IgG4, κ-type antibody inhibitor targeting IL11RA, with a K_D of 6 nM. Anti-IL11RA Antibody (X209) blocks the IL11RA signaling pathway, inhibits ERK-dependent activation, and reduces the activation level of ERK1/2. Anti-IL11RA Antibody (X209) exerts a protective effect against fibrosis. Anti-IL11RA Antibody (X209) is applicable to studies related to liver fibrosis, cardiac fibrosis and other related conditions. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003)^[1][2].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

Anti-IL11RA Antibody (X209) (24 h) inhibits the secretion of profibrotic proteins by primary human hepatic stellate cells (HSCs), with an IC₅₀ of 5.4 pM^[1].
Anti-IL11RA Antibody (X209) (2 μg/mL; 24 h) inhibits the transformation of primary human hepatic stellate cells (HSCs) into myofibroblasts induced by various NASH-related stimuli^[1].
Anti-IL11RA Antibody (X209) (2 μg/mL; 15 min pre-incubation, 48 h co-incubation) potently inhibits Matrigel invasion of primary human hepatic stellate cells (HSCs) induced by PDGF and CCL2^[1].
Anti-IL11RA Antibody (X209) (24 h) potently inhibits the secretion of MMP2 and TIMP1 by mouse and human cardiac fibroblasts stimulated with TGFβ1, with an IC₅₀ in the low nM range^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-IL11RA Antibody (X209) (10 mg/kg; s.c.; bi-weekly; 4 weeks) abolishes ERK activation, alleviates liver fibrosis and hepatocellular injury, and regulates the expression of profibrotic genes in mice with established NASH^[1].
Anti-IL11RA Antibody (X209) (10 mg/kg; i.p.; three times weekly; 7 weeks) reduces liver fibrosis levels and inflammatory gene expression in mice with advanced non-alcoholic steatohepatitis (NASH) induced by Streptozotocin (HY-13753)^[1].
Anti-IL11RA Antibody (X209) (20 mg/kg; i.p.; bi-weekly; 2 weeks) significantly attenuates AAC-induced cardiac fibrosis and ERK1/2 activation in male C57BL/6J mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145 kDa

Liquid

Colorless to light yellow

[Anti-IL11RA Antibody (X209)]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Flow Cytometry analysis of K562 cells labelling IL-11RA (red) with Anti-IL11RA Antibody (HY-P991219). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Widjaja A A, et al. IL-11 neutralising therapies target hepatic stellate cell-induced liver inflammation and fibrosis in NASH. bioRxiv, 2018: 470062.

  [2]. Lim WW, et al. Antibody-mediated neutralization of IL11 signalling reduces ERK activation and cardiac fibrosis in a mouse model of severe pressure overload. Clin Exp Pharmacol Physiol. 2021;48(4):605-613.  [Content Brief]